May 21 2010
PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
In addition, PLC will hold its first international distributor meeting, including a presentation on the status of the MYTHOS investigator-sponsored clinical trial by Dr. Antonio Bartorelli, one of the two principal investigators of the trial.
Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "EuroPCR is one of the premier international cardiovascular events of the year. Since RenalGuard could provide an important solution for patients with diminished kidney function undergoing cardiac imaging procedures, this conference gives us a strong opportunity to meet with global knowledge leaders, current and potential customers, and current and potential distributors. Our first international distributor meeting, to be held in concert with EuroPCR, provides us with an important opportunity to further educate our distribution partners about the latest scientific findings on RenalGuard's safety and efficacy, which we hope accelerates adoption of RenalGuard in the countries where it is now being marketed."
PLC recently received Notices of Allowance for four of PLC's patent applications associated with its RenalGuard technology from the U.S. Patent and Trademark Office. The company has distribution agreements covering Austria; Croatia; Russia; Belgium; the Netherlands; Luxembourg; all of the former Soviet Socialist Republic nations; Portugal; New Zealand; Portugal; China and Taiwan; Italy; Spain; Monaco; Pakistan and Bangladesh.
High testosterone levels in older men associated with greater risk of atrial fibrillation